Extending sarcoma TCR-T beyond HLA-A*02
Today's engineered T-cell therapies for sarcoma only work in the ~40-50% of people with one particular HLA type; new receptors for other HLA types would open them to everyone.
Afami-cel and lete-cel require HLA-A*02:01/02:05/02:06. MAGE-A4 and NY-ESO-1 are presented by other alleles (A*24, B*35, C*07); TCR discovery platforms (Immatics, T-knife, Adaptimmune's own) have isolated candidate receptors.
Pages like this
not linked directly; found by shared links- TrialIGNYTE-ESO
Shares Letetresgene autoleucel, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
- CompanyUS WorldMeds
Shares Letetresgene autoleucel, Afamitresgene autoleucel, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- Key paperSPEARHEAD-1: afami-cel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma
Shares Letetresgene autoleucel, Afamitresgene autoleucel, TCR-T cell therapy, Rare and paediatric cancers without markets.
- Key paperSPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma
Shares MAGE-A4, Afamitresgene autoleucel, TCR-T cell therapy, Rare and paediatric cancers without markets.
- CompanyTScan Therapeutics
Shares MAGE-A4, TCR-T cell therapy.
- CompanyAdaptimmune
Shares Afamitresgene autoleucel, Sarcomas (soft tissue, bone, GIST).
- TermHLA-A*02:01 restriction
Shares Afamitresgene autoleucel, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
- CompanySpringWorks Therapeutics (Merck KGaA)
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).